40 mg/ml
Trade Name
Yesafili
Solution for injection
Request Type
New Registration
Drug Type
Biological
Approval Date
SFDA Approved Use
Aflibercept is indicated for adults for the treatment of:
• neovascular (wet) age-related macular degeneration (AMD),
• visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO),
• visual impairment due to diabetic macular oedema (DME),
• visual impairment due to myopic choroidal neovascularisation (myopic CNV).
• neovascular (wet) age-related macular degeneration (AMD),
• visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO),
• visual impairment due to diabetic macular oedema (DME),
• visual impairment due to myopic choroidal neovascularisation (myopic CNV).